The nuvaxovid market research report is one of a series of new reports that provides nuvaxovid market statistics, including nuvaxovid industry global market size, regional shares, competitors with nuvaxovid market share, detailed nuvaxovid market segments, market trends and opportunities, and any further data you may need to thrive in the nuvaxovid industry. This nuvaxovid market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The growth in the forecast period can be attributed to increasing global demand for COVID-19 vaccines, rising investments in vaccine manufacturing capacities, growing demand for travel-related immunizations, rising income levels driving vaccine purchases, and an increase in online platforms for vaccine orders. Major trends in the forecast period include innovations in vaccine delivery methods, innovations in vaccine cold-chain logistics, partnerships with pharmaceutical companies for regional supply, technological advancements in vaccine production, and advancements in vaccine storage technology.
The increasing prevalence of infectious diseases is expected to drive the growth of the Nuvaxovid market. Infectious diseases are caused by harmful microorganisms such as bacteria, viruses, fungi, or parasites, and can spread from person to person or through the environment. Factors such as global travel, urbanization, climate change, antimicrobial resistance, and the emergence of new pathogens are contributing to the rising incidence of these diseases. Nuvaxovid plays a key role in addressing this issue by providing a vaccine to prevent COVID-19 and reduce its transmission, which helps to limit the spread of the virus worldwide. For example, in March 2023, the Office for National Statistics in the UK reported an increase in COVID-19 infections, with an estimated 2.66% of the population in England testing positive, equivalent to one in 40 people. Trends in other regions, such as Wales, Scotland, and Northern Ireland, were more uncertain, but hospital admissions and COVID-19-related deaths were rising. This growing prevalence of infectious diseases is driving the demand for Nuvaxovid.
The rising demand for vaccines is expected to further boost the Nuvaxovid market. Vaccines stimulate the immune system to help the body recognize and combat specific infectious diseases. As the prevalence of infectious diseases continues to rise, public awareness of the importance of health protection has also increased, along with advancements in vaccine development and a growing emphasis on preventive healthcare. Nuvaxovid addresses this increased demand by offering an updated vaccine solution that targets emerging COVID-19 variants, ensuring broader protection and supporting global vaccination efforts. According to the Centers for Disease Control and Prevention (CDC) in November 2024, by October 2024, 13.7% of U.S. adults had received the 2024-25 COVID-19 vaccine, while 24.5% had received the flu vaccine for the same season. Vaccination rates were highest among older adults, with 29.1% of people aged 65 and over receiving the COVID-19 vaccine and 43.1% getting the flu vaccine. This rising demand for vaccines is contributing to the growth of the Nuvaxovid market.
A key trend in the Nuvaxovid market is the development of updated vaccine formulations that address emerging COVID-19 variants, further supporting global vaccination efforts. These updated vaccines are modified versions of the original, designed to enhance protection against newly circulating variants of the SARS-CoV-2 virus and maintain effectiveness in preventing severe illness and hospitalization. For instance, in October 2024, Novavax, Inc. announced that the European Commission granted marketing authorization for its updated 2024-2025 Nuvaxovid COVID-19 vaccine for individuals aged 12 and older in the European Union. The updated vaccine targets the JN.1 lineage and offers cross-reactivity against several other variants. This approval marks a significant step in expanding access to vaccines designed to address emerging variants and supports ongoing global efforts to control the spread of COVID-19.
The key company operating in the nuvaxovid market is Novavax Inc.
North America was the largest region in the nuvaxovid market in 2024. The regions covered in nuvaxovid report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the nuvaxovid market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Nuvaxovid is a protein-based vaccine that utilizes a recombinant spike protein from the SARS-CoV-2 virus, combined with an adjuvant (Matrix-M), to enhance the immune response. It works by stimulating the immune system to recognize and combat the virus, providing protection against COVID-19. Nuvaxovid is administered as a two-dose series and is authorized in multiple countries for the prevention of COVID-19 in individuals aged 12 and older.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary uses of Nuvaxovid include initial immunization, booster doses, vaccination for immunocompromised patients, elderly populations, pediatric immunization, and travel-related vaccination. Primary immunization refers to the first series of vaccine doses given to initiate and establish long-lasting immunity against specific infectious diseases. Nuvaxovid is utilized in settings such as hospitals, clinics, ambulatory care, and home care. It is distributed through various channels, including retail pharmacies, online platforms, and government vaccination programs.
The nuvaxovid market consists of sales of nuvaxovid multidose vial and the single dose. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth in the forecast period can be attributed to increasing global demand for COVID-19 vaccines, rising investments in vaccine manufacturing capacities, growing demand for travel-related immunizations, rising income levels driving vaccine purchases, and an increase in online platforms for vaccine orders. Major trends in the forecast period include innovations in vaccine delivery methods, innovations in vaccine cold-chain logistics, partnerships with pharmaceutical companies for regional supply, technological advancements in vaccine production, and advancements in vaccine storage technology.
The increasing prevalence of infectious diseases is expected to drive the growth of the Nuvaxovid market. Infectious diseases are caused by harmful microorganisms such as bacteria, viruses, fungi, or parasites, and can spread from person to person or through the environment. Factors such as global travel, urbanization, climate change, antimicrobial resistance, and the emergence of new pathogens are contributing to the rising incidence of these diseases. Nuvaxovid plays a key role in addressing this issue by providing a vaccine to prevent COVID-19 and reduce its transmission, which helps to limit the spread of the virus worldwide. For example, in March 2023, the Office for National Statistics in the UK reported an increase in COVID-19 infections, with an estimated 2.66% of the population in England testing positive, equivalent to one in 40 people. Trends in other regions, such as Wales, Scotland, and Northern Ireland, were more uncertain, but hospital admissions and COVID-19-related deaths were rising. This growing prevalence of infectious diseases is driving the demand for Nuvaxovid.
The rising demand for vaccines is expected to further boost the Nuvaxovid market. Vaccines stimulate the immune system to help the body recognize and combat specific infectious diseases. As the prevalence of infectious diseases continues to rise, public awareness of the importance of health protection has also increased, along with advancements in vaccine development and a growing emphasis on preventive healthcare. Nuvaxovid addresses this increased demand by offering an updated vaccine solution that targets emerging COVID-19 variants, ensuring broader protection and supporting global vaccination efforts. According to the Centers for Disease Control and Prevention (CDC) in November 2024, by October 2024, 13.7% of U.S. adults had received the 2024-25 COVID-19 vaccine, while 24.5% had received the flu vaccine for the same season. Vaccination rates were highest among older adults, with 29.1% of people aged 65 and over receiving the COVID-19 vaccine and 43.1% getting the flu vaccine. This rising demand for vaccines is contributing to the growth of the Nuvaxovid market.
A key trend in the Nuvaxovid market is the development of updated vaccine formulations that address emerging COVID-19 variants, further supporting global vaccination efforts. These updated vaccines are modified versions of the original, designed to enhance protection against newly circulating variants of the SARS-CoV-2 virus and maintain effectiveness in preventing severe illness and hospitalization. For instance, in October 2024, Novavax, Inc. announced that the European Commission granted marketing authorization for its updated 2024-2025 Nuvaxovid COVID-19 vaccine for individuals aged 12 and older in the European Union. The updated vaccine targets the JN.1 lineage and offers cross-reactivity against several other variants. This approval marks a significant step in expanding access to vaccines designed to address emerging variants and supports ongoing global efforts to control the spread of COVID-19.
The key company operating in the nuvaxovid market is Novavax Inc.
North America was the largest region in the nuvaxovid market in 2024. The regions covered in nuvaxovid report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the nuvaxovid market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Nuvaxovid is a protein-based vaccine that utilizes a recombinant spike protein from the SARS-CoV-2 virus, combined with an adjuvant (Matrix-M), to enhance the immune response. It works by stimulating the immune system to recognize and combat the virus, providing protection against COVID-19. Nuvaxovid is administered as a two-dose series and is authorized in multiple countries for the prevention of COVID-19 in individuals aged 12 and older.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary uses of Nuvaxovid include initial immunization, booster doses, vaccination for immunocompromised patients, elderly populations, pediatric immunization, and travel-related vaccination. Primary immunization refers to the first series of vaccine doses given to initiate and establish long-lasting immunity against specific infectious diseases. Nuvaxovid is utilized in settings such as hospitals, clinics, ambulatory care, and home care. It is distributed through various channels, including retail pharmacies, online platforms, and government vaccination programs.
The nuvaxovid market consists of sales of nuvaxovid multidose vial and the single dose. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Nuvaxovid Market Characteristics4. Nuvaxovid Market Trends And Strategies5. Nuvaxovid Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market7. Global Nuvaxovid Pricing Analysis & Forecasts30. Global Nuvaxovid Market Competitive Benchmarking And Dashboard31. Key Mergers And Acquisitions In The Nuvaxovid Market32. Recent Developments In The Nuvaxovid Market
3. Nuvaxovid Market Biologic Drug Characteristics
6. Global Nuvaxovid Growth Analysis And Strategic Analysis Framework
8. Nuvaxovid Market Segmentation
9. Global Nuvaxovid Epidemiology Of Clinical Indications
10. Nuvaxovid Market Regional And Country Analysis
11. Asia-Pacific Nuvaxovid Market
12. China Nuvaxovid Market
13. India Nuvaxovid Market
14. Japan Nuvaxovid Market
15. Australia Nuvaxovid Market
16. South Korea Nuvaxovid Market
17. Western Europe Nuvaxovid Market
18. UK Nuvaxovid Market
19. Germany Nuvaxovid Market
20. France Nuvaxovid Market
21. Eastern Europe Nuvaxovid Market
22. North America Nuvaxovid Market
23. USA Nuvaxovid Market
24. Canada Nuvaxovid Market
25. South America Nuvaxovid Market
26. Middle East Nuvaxovid Market
27. Africa Nuvaxovid Market
28. Nuvaxovid Market Competitive Landscape And Company Profiles
29. Global Nuvaxovid Market Pipeline Analysis
33. Nuvaxovid Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Nuvaxovid Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on nuvaxovid market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for nuvaxovid ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The nuvaxovid market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Clinical Indication: Primary Immunization; Booster Immunization; Immunocompromised Patients; Elderly Population; Pediatric Immunization; Travel Immunization2) By End Use: Hospitals; Clinics; Ambulatory Care; Home Care
3) By Distribution Channel: Retail Pharmacies; Online Sales; Government Programs
Key Companies Profiled: Novavax Inc.
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Novavax Inc.
